Radiofrequency Ablation Guided by CartoUnivu and Carto3 Intelligent Systems for the Treatment of Tachyarrhythmia: Randomized Controlled Trial (Preprint)

BACKGROUND Radiofrequency ablation has obvious advantages in the treatment of arrhythmia, like few postoperative complications, high cure rate, low recurrence rate, and low trauma, and it has become the first choice to treat patients with arrhythmia. OBJECTIVE This paper aims to determine the x-ray dose associated with radiofrequency ablation, guided by the CartoUnivu (Biosense Webster Inc) and Carto3 (Biosense Webster Inc) intelligent systems in patients with paroxysmal supraventricular tachycardia (PSVT) and patients with premature ventricular contractions (PVC) and ventricular tachycardia (VT) arrhythmia. METHODS Radiofrequency ablation guided by the CartoUnivu and Carto3 systems was used to treat patients with PSVT and patients with PVC and VT arrhythmia, and the x-ray doses delivered to the thyroid, perineum, left upper arm, intrathyroid, extrathyroid, intrathoracic region, extrathoracic region, intraperineum, extraperineum, and other parts of the body during the treatment were analyzed. RESULTS In most patients with PSVT, radiofrequency ablation guided by the Carto3 system had a lower x-ray dose than that of CartoUnivu. Radiofrequency ablation under the guidance of the CartoUnivu system resulted in lower x-ray radiation for patients with PVC and VT. CONCLUSIONS The CartoUnivu and Carto3 systems can guide the precise treatment of complex arrhythmia, have a high success rate and good safety, reduce the x-ray exposure time and dose received by patients and operators, and reduce the risk of x-ray–related damage and are therefore worth promoting.